- Home
- ALDX vs CVRX Comparison
ALDX vs CVRX Comparison
Compare ALDX & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- CVRX
- Stock Information
- Founded
- ALDX 2004
- CVRX 2000
- Country
- ALDX United States
- CVRX United States
- Employees
- ALDX N/A
- CVRX N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ALDX Health Care
- CVRX Health Care
- Exchange
- ALDX Nasdaq
- CVRX Nasdaq
- Market Cap
- ALDX 160.8M
- CVRX 174.4M
- IPO Year
- ALDX 2014
- CVRX 2021
- Fundamental
- Price
- ALDX $4.76
- CVRX $6.86
- Analyst Decision
- ALDX Strong Buy
- CVRX Buy
- Analyst Count
- ALDX 2
- CVRX 7
- Target Price
- ALDX $9.50
- CVRX $14.50
- AVG Volume (30 Days)
- ALDX 1.2M
- CVRX 171.6K
- Earning Date
- ALDX 07-31-2025
- CVRX 07-28-2025
- Dividend Yield
- ALDX N/A
- CVRX N/A
- EPS Growth
- ALDX N/A
- CVRX N/A
- EPS
- ALDX N/A
- CVRX N/A
- Revenue
- ALDX N/A
- CVRX $52,870,000.00
- Revenue This Year
- ALDX N/A
- CVRX $11.53
- Revenue Next Year
- ALDX N/A
- CVRX $18.61
- P/E Ratio
- ALDX N/A
- CVRX N/A
- Revenue Growth
- ALDX N/A
- CVRX 25.62
- 52 Week Low
- ALDX $1.14
- CVRX $4.30
- 52 Week High
- ALDX $7.20
- CVRX $18.55
- Technical
- Relative Strength Index (RSI)
- ALDX 78.74
- CVRX 61.51
- Support Level
- ALDX $4.12
- CVRX $6.30
- Resistance Level
- ALDX $4.60
- CVRX $7.21
- Average True Range (ATR)
- ALDX 0.29
- CVRX 0.35
- MACD
- ALDX 0.08
- CVRX 0.16
- Stochastic Oscillator
- ALDX 90.91
- CVRX 83.24
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.